Please login to the form below

Not currently logged in
Email:
Password:

PD-1 inhibitor

This page shows the latest PD-1 inhibitor news and features for those working in and with pharma, biotech and healthcare.

BMS CEO tackles investor ‘frustrations’ on immuno-oncology

BMS CEO tackles investor ‘frustrations’ on immuno-oncology

BMS was the pathfinder for the checkpoint inhibitor market with its CTLA4 inhibitor Yervoy (ipilimumab) and PD-1 blocker Opdivo (nivolumab), However, it has since lost ground to rival Merck ... MSD, whose PD-1 drug Keytruda (pembrolizumab) outsold Opdivo

Latest news

  • Dynavax is ‘deal-ready’ after solid ESMO data; analyst Dynavax is ‘deal-ready’ after solid ESMO data; analyst

    Updated results from a trial of the toll-like receptor 9 (TLR9) agonist given alongside Merck &Co/MSD’s PD-1 inhibitor Keytruda (pembrolizumab) in melanoma and head-and-neck squamous ... The results in PD-1 inhibitor-naïve melanoma patients,

  • Keytruda hits survival targets in first-line kidney cancer Keytruda hits survival targets in first-line kidney cancer

    cancer. The US drugmaker – known as MSD outside North America – has just unveiled the results of its phase 3 KEYNOTE-426 trial of PD-1 inhibitor Keytruda (pembrolizumab) in combination with ... Bristol-Myers Squibb’s cancer immunotherapy pairing of

  • China’s Innovent to start US trials of anti-CD47 cancer drug China’s Innovent to start US trials of anti-CD47 cancer drug

    trials after PD-1 inhibitor sintilimab (IBI-308) – partnered with Eli Lilly – got a green light earlier this year. ... Sintilimab is being positioned initially for the Chinese market, given the wealth of competition in the PD-1/PD-L1 inhibitor

  • Roche’s Tecentriq misses survival mark in frontline NSCLC Roche’s Tecentriq misses survival mark in frontline NSCLC

    endpoint. Roche’s PD-L1 inhibitor Tecentriq (pemetrexed) was unable to meet the threshold for a significant improvement in overall survival (OS) when added to Eli Lilly’s Alimta (pemetrexed) and ... The company is still hoping that Tecentriq will hit

  • NICE turns down Opdivo for adjuvant melanoma therapy NICE turns down Opdivo for adjuvant melanoma therapy

    England's cost effectiveness watchdog NICE has decided not to recommend use of the PD-1 inhibitor as an adjuvant treatment for NHS patients with stage III and IV melanoma – in ... At the moment Opdivo is the only PD-1-targeted cancer immunotherapy

More from news
Approximately 3 fully matching, plus 177 partially matching documents found.

Latest Intelligence

  • Deal Watch January 2017 Deal Watch January 2017

    3, 050. Pieris Pharmaceuti-cals. Servier. Exclusive licence outside USA. PRS 332 PD-1-targeting bispecific checkpoint inhibitor and 4 other candidates. ... 775. BMS | Ono. Merck. Patent settlement. PD-1 antibody Keytruda - (pembrolizumab).

  • Pharma deals in September 2015 Pharma deals in September 2015

    taking rights (outside China) to a PD-1 inhibitor (POC ready) from Jaingsu Hengrui Medicine (SHR-1210) for advanced solid tumours paying a modest $25m upfront but up to $770m in ... Acquisition - company. 1, 230. Jiangsu Hengrui Medicine. Incyte.

  • Deal Watch table for November 2014 Deal Watch table for November 2014

    PD-L1 and PD-1 CP inhibitors. Co-development and co-marketing alliance. 2, 850. ... FPA008 mAb inhibits (CSF1R) to be combined with nivolumab (PD-1 check-point inhibitor).

  • Pharma deals during October 2014 Pharma deals during October 2014

    Medivation closed an exclusive worldwide licence with rights to CureTech's pidilizumab (CT-011), an immune modulatory anti-PD-1 monoclonal antibody. ... The phase 1/2 studies will assess Novartis' Zykadia [ceritinib], INC 280 and EGF 816 in combination

More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Merrill Brink International

Merrill Brink International is a leading provider of life sciences, legal, financial, manufacturing and corporate language solutions for global companies....

Latest intelligence

World Pancreatic Cancer Day 2018: Combating misconceptions in pancreatic cancer
Patients diagnosed with pancreatic cancer face a dismal prognosis, with the disease having the lowest survival rate of all major cancers. In spite of this, pancreatic cancer research is chronically...
World Diabetes Day: Interaction and impact of diabetes on mental health
For World Diabetes Day on the 14th November 2018, Nisha Shahrukh - Medical Writer at Mednet Group has written an article depicting the impact diabetes has on mental health. Including...
EU
Innovation in merger control and the impact on the pharmaceutical sector
Is focusing on pipeline products enough to assess regulatory risks?...

Infographics